acute lymphoblastic leukemia
Conditions
Interventions
In CD19-positive nonPh ALL, blinatumomab (Blina) is used as an upfront to achieve MRD-negative conversion and maintenance. In CD19-negative nonPh ALL, allogeneic hematopoietic stem cell transplantatio
Sponsors
Koichi Akashi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Cases diagnosed with acute lymphocytic leukemia in the WHO classification (2017) with more than 26% blasts in the bone marrow, or mixed phenotype acute leukemia (MPAL) in the WHO classification (2017). Patients with more than 26% blasts in the bone marrow and undergoing ALL-directed chemotherapy. The WHO classification (2017 edition) is used as the diagnostic criteria for MPAL in this study. 3.First-time treatment patients who have not received chemotherapy or radiotherapy. 3.Patients aged between 16 and 65 years old. 4.Performance status (ECOG): 0 to 2 cases. 5.Cases without severe organ damage. T. Bil=<2.0mg/dL, Cr=<2.0mg/dL 6.Patients who have given written consent from the patient after explaining the content of this research. However, in the case of minors, written consent has been obtained from the legal representative and the individual.
Exclusion criteria
Exclusion criteria: 1. Blast cell surface immunoglobulin-positive Burkitt leukemia. 2.Patients with active double cancer. 3.Patients with difficult-to-control infections. 4. Cases with severe mental disorders. 5. Pregnant cases. 6.Other cases judged inappropriate by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3-year disease-free survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| 3-year/5-year overall survival rate, 5-year disease-free survival rate, 3-year/5-year complete remission rate, remission rate (CR, MRDneg), protocol completion rate, treatment-related death (TRM) rate, adverse event rate | — |
Contacts
Public ContactShima Takahiro
Kyushu University Hospital
Outcome results
None listed